AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10706042 — intervention group
Group type: COMPARATOR
Intervention: No CMV infection
Number of subjects: 0
Study 9113632 — intervention group
Group type: EXPERIMENTAL
Intervention: High-AA diet (1.7 g/d of arachidonic acid for 50 d)
Number of subjects: 10
Study 9113632 — intervention group
Group type: COMPARATOR
Intervention: Low-AA diet (210 mg/d of AA)
Number of subjects: 10
Study 8403299 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-383 (0.4 microgram.kg-1 x min-1)
Number of subjects: 33
Study 8403299 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-383 (0.15 to 0.2 microgram.kg-1 x min-1)
Number of subjects: 33
Study 8403299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3100859 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acyclovir (ACV)
Number of subjects: 0
Study 3100859 — intervention group
Group type: COMPARATOR
Intervention: Trifluorothymidine (TFT)
Number of subjects: 0
Study 30014968 — intervention group
Group type: EXPERIMENTAL
Intervention: Light load blood flow restriction resistance exercise (BFR‐RE) in ACLR patients (ACLR‐BFR)
Number of subjects: 3
Study 30014968 — intervention group
Group type: COMPARATOR
Intervention: Light load blood flow restriction resistance exercise (BFR‐RE) in non-injured individuals (NI‐BFR)
Number of subjects: 3
Study 30014968 — intervention group
Group type: COMPARATOR
Intervention: Heavy load resistance exercise (HL‐RE) in ACLR patients (ACLR‐HL)
Number of subjects: 3
Study 30014968 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Number of subjects: 3
Study 28065190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1250μg (50 000 IU) weekly for 12 weeks
Number of subjects: 44
Study 28065190 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol 1250μg (50 000 IU) weekly for 12 weeks
Number of subjects: 44
Study 28065190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol and Ergocalciferol
Number of subjects: 44
Study 24410959 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (0, 6, 12, or 18 sessions)
Number of subjects: 400
Study 24410959 — intervention group
Group type: COMPARATOR
Intervention: Light massage control
Number of subjects: 400
Study 22317388 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved weeding tools
Number of subjects: 60
Study 22317388 — intervention group
Group type: COMPARATOR
Intervention: Traditional tools
Number of subjects: 60
Study 20799571 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy (SAH)
Number of subjects: 150
Study 20799571 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 150
Study 18467303 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration antimicrobial treatment (5 days)
Number of subjects: 3083
Study 16874507 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly smokers
Number of subjects: 53
Study 16874507 — intervention group
Group type: COMPARATOR
Intervention: Elderly smokers with 2 h abstinence
Number of subjects: 53
Study 16874507 — intervention group
Group type: COMPARATOR
Intervention: Young non-smokers
Number of subjects: 53
Study 12511761 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Family Support Organiser (FSO) service
Number of subjects: 250
Study 12511761 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 250
Study 10728021 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (MAC)
Number of subjects: 23
Study 10728021 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol consuming patients (Control)
Number of subjects: 23
Study 8649628 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporin A
Number of subjects: 302
Study 1308013 — intervention group
Group type: EXPERIMENTAL
Intervention: Air pollution exposure in Parel (SO2 levels up to 584 micrograms)
Number of subjects: 349
Study 1308013 — intervention group
Group type: EXPERIMENTAL
Intervention: Air pollution exposure in Maravali
Number of subjects: 349
Study 1308013 — intervention group
Group type: EXPERIMENTAL
Intervention: Kerosene use
Number of subjects: 349
Study 1308013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function tests (FVC, FEVI)
Number of subjects: 349
Study 1308013 — intervention group
Group type: COMPARATOR
Intervention: Air pollution exposure in Deonar
Number of subjects: 349
Study 3912600 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 50
Study 3912600 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% levobunolol
Number of subjects: 50
Study 3912600 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 50
Study 31307055 — intervention group
Group type: EXPERIMENTAL
Intervention: CA+CSP
Number of subjects: 184
Study 31307055 — intervention group
Group type: COMPARATOR
Intervention: HB+HSP
Number of subjects: 184
Study 28700781 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose spironolactone (100 mg)
Number of subjects: 360
Study 28700781 — intervention group
Group type: COMPARATOR
Intervention: Usual care (placebo or 25 mg spironolactone)
Number of subjects: 360
Study 27518920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy at walking pace
Number of subjects: 10
Study 27518920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy at walk-trot pace
Number of subjects: 10
Study 27518920 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no treatment)
Number of subjects: 10
Study 25163664 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS and RE-AIM frameworks
Number of subjects: 0
Study 22045829 — intervention group
Group type: EXPERIMENTAL
Intervention: tesaglitazar 2 mg
Number of subjects: 0
Study 22045829 — intervention group
Group type: COMPARATOR
Intervention: pioglitazone 45 mg
Number of subjects: 0
Study 22045829 — intervention group
Group type: EXPERIMENTAL
Intervention: tesaglitazar 2 mg with ACE inhibitor
Number of subjects: 0
Study 19707060 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback
Number of subjects: 0
Study 17290158 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (70 mg/day) + exercise program (3 times per week)
Number of subjects: 50
Study 17290158 — intervention group
Group type: COMPARATOR
Intervention: Exercise program (3 times per week)
Number of subjects: 50
Study 15625409 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cilostazol
Number of subjects: 12
Study 15625409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11717205 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 6
Study 11717205 — intervention group
Group type: COMPARATOR
Intervention: Upright position
Number of subjects: 6
Study 9602004 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 120
Study 9602004 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 120
Study 8150535 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical cystectomy and pelvic-node dissection followed by adjuvant cisplatinum chemotherapy
Number of subjects: 70
Study 8150535 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy and pelvic-node dissection alone
Number of subjects: 70
Study 8150535 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant carcinoma in situ
Number of subjects: 70
Study 8150535 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of invasion
Number of subjects: 70
Study 8150535 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological variables (deep invasion of the bladder wall and squamous differentiation)
Number of subjects: 70
Study 8150535 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiation grade, pattern of growth, angioinvasive growth, glandular differentiation, concomitant prostate carcinoma (pT1)
Number of subjects: 70
Study 2892392 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 75 mg
Number of subjects: 8
Study 2892392 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 8
Study 2892392 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 8
Study 2892392 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 8
Study 2892392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31039294 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst spinal cord stimulation (SCS)
Number of subjects: 7
Study 31039294 — intervention group
Group type: COMPARATOR
Intervention: Tonic spinal cord stimulation (SCS)
Number of subjects: 7
Study 30987919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free fruit drinks
Number of subjects: 89
Study 30987919 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened fruit drinks
Number of subjects: 89
Study 28421316 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroclavicular approach (group R)
Number of subjects: 100
Study 28421316 — intervention group
Group type: COMPARATOR
Intervention: Coracoid approach (group C)
Number of subjects: 100
Study 25731690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg daily) until 34 weeks and 6 days' gestation
Number of subjects: 390
Study 25731690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 24356937 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heart rate >70 bpm
Number of subjects: 31531
Study 24356937 — intervention group
Group type: EXPERIMENTAL
Intervention: Average heart rate in-trial
Number of subjects: 31531
Study 24356937 — intervention group
Group type: EXPERIMENTAL
Intervention: For each 10 bpm increase in baseline and average heart rate
Number of subjects: 31531
Study 24356937 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate as a continuous variable
Number of subjects: 31531
Study 24356937 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate quintiles
Number of subjects: 31531
Study 24356937 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 31531
Study 21945107 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-pelvis concurrent chemoradiation (WP-CCRT)
Number of subjects: 230
Study 21945107 — intervention group
Group type: COMPARATOR
Intervention: Bladder-only concurrent chemoradiation (BO-CCRT)
Number of subjects: 230
Study 19390070 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe cerebral white matter hyperintensities (WMHs)
Number of subjects: 226
Study 19390070 — intervention group
Group type: COMPARATOR
Intervention: No severe WMHs
Number of subjects: 226
Study 17469099 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week, increased every 3 months if Disease Activity Score >2.4, tapered after 12 months
Number of subjects: 110
Study 17469099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 17469099 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 110
Study 15262695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/d
Number of subjects: 8
Study 15262695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 or 200 mg/d (after randomization)
Number of subjects: 8
Study 15262695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide treatment
Number of subjects: 8
Study 15262695 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathy Impairment Score
Number of subjects: 8
Study 15262695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sural sensory nerve action potential amplitude
Number of subjects: 8
Study 12225503 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg)
Number of subjects: 0
Study 12225503 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (40 mg/kg)
Number of subjects: 0
Study 12225503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine (500 mg) and Pyrimethamine (25 mg)
Number of subjects: 0
Study 12225503 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (30 mg/kg)
Number of subjects: 0
Study 9522107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg once daily
Number of subjects: 469
Study 9522107 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 500 mg three times daily
Number of subjects: 469
Study 9308538 — intervention group
Group type: EXPERIMENTAL
Intervention: fixed angle blade plate
Number of subjects: 233
Study 9308538 — intervention group
Group type: EXPERIMENTAL
Intervention: compression hip screw
Number of subjects: 233
Study 9308538 — intervention group
Group type: COMPARATOR
Intervention: implants not removed
Number of subjects: 233
Study 2118025 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Care Unit (CCU)
Number of subjects: 203
Study 2118025 — intervention group
Group type: COMPARATOR
Intervention: General Wards (GW)
Number of subjects: 203
Study 7213519 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25, 50, 100 and 200 mg daily
Number of subjects: 15
Study 7213519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7213519 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 15
Study 31883378 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c > 8.0%
Number of subjects: 549
Study 31883378 — intervention group
Group type: COMPARATOR
Intervention: HbA1c 6.1-7.0%
Number of subjects: 549
Study 31883378 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≤ 6.0%
Number of subjects: 549
Study 30574780 — intervention group
Group type: EXPERIMENTAL
Intervention: High-catechin tea (HCT)
Number of subjects: 10
Study 30574780 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 10
Study 29063827 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab injections (80 mg and then 40 mg 2 weeks later) plus physiotherapy
Number of subjects: 332
Study 29063827 — intervention group
Group type: COMPARATOR
Intervention: Saline injections plus physiotherapy
Number of subjects: 332
Study 26407612 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC conical-shaped tracheal tube
Number of subjects: 312
Study 26407612 — intervention group
Group type: COMPARATOR
Intervention: PVC standard (barrel)-shaped tracheal tube
Number of subjects: 312
Study 25524507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 mcg
Number of subjects: 309
Study 25524507 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 500 mcg
Number of subjects: 309
Study 23751521 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 14
Study 23751521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21975110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (Circadin®) 2 mg daily
Number of subjects: 80
Study 21975110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19594263 — intervention group
Group type: EXPERIMENTAL
Intervention: Food advertising during TV viewing (children)
Number of subjects: 2
Study 19594263 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack food advertising (adults)
Number of subjects: 2
Study 19594263 — intervention group
Group type: COMPARATOR
Intervention: No food advertising (adults)
Number of subjects: 2
Study 19594263 — intervention group
Group type: COMPARATOR
Intervention: Food advertising promoting nutrition benefits (adults)
Number of subjects: 2
Study 17033041 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness Through Movement (ATM)
Number of subjects: 33
Study 17033041 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 15017504 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/day
Number of subjects: 57
Study 15017504 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine 1 g 3 times/day
Number of subjects: 57
Study 11156722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (0.1 microg/kg/min intravenously) + Enoxaparin (1 mg/kg sc q 12 hours)
Number of subjects: 55
Study 11156722 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban (0.1 microg/kg/min intravenously) + Unfractionated heparin (intravenous, adjusted to activated partial thromboplastin time)
Number of subjects: 55
Study 9660035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 28 days prior to zolmitriptan administration
Number of subjects: 20
Study 9660035 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 28 days prior to zolmitriptan administration
Number of subjects: 20
Study 9660035 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg oral dose
Number of subjects: 20
Study 9660035 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan alone or with fluoxetine
Number of subjects: 20
Study 7972763 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐1 MR spectroscopy
Number of subjects: 20
Study 7972763 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo‐inositol depletion
Number of subjects: 20
Study 2521032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's with 5% dextrose (LR5%D), 1 minute
Number of subjects: 80
Study 2521032 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's with 5% dextrose (LR5%D), 2 minutes
Number of subjects: 80
Study 2521032 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's (LR), 1 minute
Number of subjects: 80
Study 2521032 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's (LR), 2 minutes
Number of subjects: 80
Study 50126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin intramuscularly
Number of subjects: 15
Study 50126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin via continuous infusion
Number of subjects: 15
Study 29156985 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated Lumbar Extension (ILEX) exercise for the lumbar extensors, 12-week intervention
Number of subjects: 9
Study 31628043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg twice daily plus best supportive care
Number of subjects: 768
Study 31628043 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo plus best supportive care
Number of subjects: 768
Study 29131730 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (10-week trauma-focused yoga program)
Number of subjects: 50
Study 29131730 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 50
Study 25038079 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week cycle ergometer-based training at moderate exertion
Number of subjects: 24
Study 25038079 — intervention group
Group type: COMPARATOR
Intervention: Control period (similar to training period)
Number of subjects: 24
Study 23525448 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI-697 600 mg
Number of subjects: 0
Study 23525448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23525448 — intervention group
Group type: EXPERIMENTAL
Intervention: P-selectin-blocking antibody (CLB-Thromb6)
Number of subjects: 0
Study 22040180 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Focus
Number of subjects: 105
Study 22040180 — intervention group
Group type: COMPARATOR
Intervention: Classic suture ligation
Number of subjects: 105
Study 19236499 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric CT-based i.v. thrombolysis after 3-9 h of symptom onset
Number of subjects: 200
Study 19236499 — intervention group
Group type: COMPARATOR
Intervention: Standard CT-based thrombolysis within 3 h
Number of subjects: 200
Study 19236499 — intervention group
Group type: COMPARATOR
Intervention: CT-based thrombolysis or placebo after 3-6 h
Number of subjects: 200
Study 16846587 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly betamethasone
Number of subjects: 495
Study 16846587 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 495
Study 12618675 — intervention group
Group type: EXPERIMENTAL
Intervention: Akinosi technique
Number of subjects: 56
Study 12618675 — intervention group
Group type: COMPARATOR
Intervention: Conventional mandibular nerve block
Number of subjects: 56
Study 12618675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 56
Study 10681341 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (1,920 mg over 3 days, four doses)
Number of subjects: 266
Study 10681341 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (2,780 mg over 3 days, six doses)
Number of subjects: 266
Study 10681341 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (2,780 mg over 5 days, six doses)
Number of subjects: 266
Study 10681341 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal meal close to drug administration
Number of subjects: 266
Study 10681341 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose regimens (B and C)
Number of subjects: 266
Study 9085958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% at 6, 8, 10, 12, or 14 mL/h for 21 hours
Number of subjects: 125
Study 9085958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 125
Study 9085958 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 125
Study 7881655 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection methods for FEV1
Number of subjects: 5885
Study 7881655 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection methods for FVC
Number of subjects: 5885
Study 7881655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean of the three highest values and the largest single value from all maneuvers
Number of subjects: 5885
Study 2689262 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 61
Study 2689262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 31612079 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (AAE) on a treadmill at 60% of VO2max for 30 min
Number of subjects: 24
Study 31612079 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean black raspberry (KBR)
Number of subjects: 24
Study 31612079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28774461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15mg/kg every 3 weeks) with carboplatin (AUC 5) and weekly paclitaxel (80mg/m2) for at least 6 cycles
Number of subjects: 33
Study 28774461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy
Number of subjects: 33